We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$5.05B
1-Year Est. Return
125.28%
This Fund
S&P 500
This Quarter
Est. Return
-2.61%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$10.7B
AUM Growth
-$733M
(-6.4%)
Cap. Flow
+$511M
Cap. Flow
% of AUM
4.78%
Top 10 Holdings %
Top 10 Hldgs %
33.24%
Holding
188
New
39
Increased
39
Reduced
24
Closed
30
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edgewise Therapeutics
EWTX
|
+$452M |
| 2 |
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
|
+$186M |
| 3 |
CMMB
Chemomab Therapeutics
CMMB
|
+$128M |
| 4 |
Haemonetics
HAE
|
+$105M |
| 5 |
Disc Medicine
IRON
|
+$86.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Prelude Therapeutics
PRLD
|
+$369M |
| 2 |
PRVL
Prevail Therapeutics Inc. Common Stock
PRVL
|
+$319M |
| 3 |
Pfizer
PFE
|
+$133M |
| 4 |
Biogen
BIIB
|
+$121M |
| 5 |
Centene
CNC
|
+$120M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 94.88% |
| 2 | Technology | 0.12% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SWTX
1
DELISTED
SpringWorks Therapeutics
SWTX
| $455M | 4.26% |
6,186,307
-1,220,000
| -16% | -$95.5M |
|
|
2
Edgewise Therapeutics
EWTX
$4.34B
| $453M | 4.24% |
+13,944,680
| New | +$452M |
|
|
3
Prelude Therapeutics
PRLD
$370M
| $435M | 4.07% |
10,039,691
-5,555,186
| -36% | -$369M |
|
4
ARS Pharmaceuticals
SPRY
$563M
| $381M | 3.57% |
8,740,887
| – | – |
|
|
HZNP
5
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $289M | 2.71% |
3,144,355
+135,600
| +5% | +$11.4M |
|
6
Merck
MRK
$326B
| $288M | 2.69% |
3,911,555
+1,124,609
| +40% | +$83M |
|
7
Bristol-Myers Squibb
BMY
$130B
| $285M | 2.67% |
4,515,400
+966,300
| +27% | +$60.1M |
|
8
AbCellera Biologics
ABCL
$1.62B
| $278M | 2.6% |
8,200,768
-200,000
| -2% | -$7.97M |
|
9
Boston Scientific
BSX
$68.5B
| $267M | 2.5% |
6,920,600
+397,600
| +6% | +$15M |
|
10
Vertex Pharmaceuticals
VRTX
$124B
| $244M | 2.28% |
1,135,900
+301,800
| +36% | +$66.3M |
|
11
PMV Pharmaceuticals
PMVP
$58.7M
| $241M | 2.25% |
7,330,423
| – | – |
|
|
TPTX
12
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $223M | 2.09% |
2,361,327
-384,000
| -14% | -$45.7M |
|
13
Natera
NTRA
$36.1B
| $223M | 2.08% |
2,195,900
+85,200
| +4% | +$9.34M |
|
14
Iovance Biotherapeutics
IOVA
$2.1B
| $210M | 1.97% |
6,645,100
| – | – |
|
|
MRTX
15
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $209M | 1.96% |
1,221,200
+75,900
| +7% | +$15M |
|
16
Arcutis Biotherapeutics
ARQT
$3.55B
| $176M | 1.64% |
6,073,850
| – | – |
|
17
Xtant Medical Holdings
XTNT
$59.7M
| $172M | 1.61% |
72,873,494
+70,422
| +0.1% | +$150K |
|
18
UnitedHealth
UNH
$389B
| $150M | 1.4% |
403,000
+12,700
| +3% | +$4.4M |
|
19
Guardant Health
GH
$19B
| $149M | 1.4% |
977,400
+439,200
| +82% | +$66.4M |
|
20
Humana
HUM
$46.7B
| $131M | 1.23% |
313,600
+27,500
| +10% | +$11M |
|
21
AbbVie
ABBV
$465B
| $131M | 1.23% |
1,213,200
+350,900
| +41% | +$37.5M |
|
22
Theravance Biopharma
TBPH
$875M
| $127M | 1.19% |
6,219,110
| – | – |
|
23
Neurocrine Biosciences
NBIX
$18.4B
| $127M | 1.18% |
1,301,715
| – | – |
|
24
Passage Bio
PASG
$14.7M
| $122M | 1.14% |
348,145
| – | – |
|
|
GRCL
25
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
| $121M | 1.14% |
+7,884,870
| New | +$186M |
|
Similar funds
HSA
LIM
NL
BPWM
LFG
JIM
CTC
PAMP
OrbiMed's Q1 2021 Portfolio in Review
As of Q1 2021, OrbiMed held 188 positions worth $10.7B, down 6.4% from $11.4B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
OrbiMed deployed $511M of net new capital in Q1 2021, opening 39 new positions and adding to 39 existing holdings. Its largest new stake was Edgewise Therapeutics: 13,944,680 shares worth $453M.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 98% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Prelude Therapeutics, an estimated $369M trimmed.
- OrbiMed's largest Q1 2021 buy was Edgewise Therapeutics: 13,944,680 shares worth $453M.
- OrbiMed added most to Merck in Q1 2021, an estimated $83M increase.
- OrbiMed's biggest Q1 2021 reduction was Prelude Therapeutics, cutting an estimated $369M.
- OrbiMed fully exited Prevail Therapeutics Inc. Common Stock in Q1 2021, selling an estimated $319M.
- OrbiMed's ten largest holdings make up 33% of its $10.7B portfolio in Q1 2021.
- OrbiMed opened 39 new positions and closed 30 in Q1 2021.
- OrbiMed's portfolio value fell 6.4% quarter-over-quarter to $10.7B.
Based on OrbiMed's 13F filing for Q1 2021, filed 17 May 2021.